Colon cancer
Specific antibodies:
The antibody Cetuximab
Cetuximab is a monoclonal antibody that targets tumor cells on the EGFR pathway and is used to treat advanced phases of EGFR-positive colon cancer in patients.
The drug Bevacizumab
It is a monoclonal antibody that inhibits the growth of tumors in blood vessels, thereby killing tumor cells on the VEGFR/VEG pathway. The first-line treatment for patients with advanced colon cancer is bevacizumab.
The Ramucircumcab
Targeting the VEGFR2/VEGF pathway, monoclonal antibody immunotherapy is the optimal treatment for patients with advanced colon cancer.
The drug Panitumumab
It is a monoclonal antibody that targets tumors on the EGFR pathway and is most effective in patients with metastatic EGFR-positive colon cancer.
Immunotherapy is one of the most effective cancer treatments with fewer adverse effects, a higher likelihood of survival, and a higher quality of life, but it is also quite expensive. Combination drugs, multiple drugs, and cancer vaccines can be extremely costly for patients. In addition, the extended duration of immunotherapy due to the use of potentially potent drugs or vaccines and multiple cycles of treatment for certain patients can be extremely expensive.
